SEOM clinical guideline for the management of malignant melanoma (2017)

All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can b...

Descripción completa

Detalles Bibliográficos
Autores: Berrocal, A., Arance, A., Castellón, V. E., Cruz Merino, Luis de la, Espinosa, E., Cao, M. G., Larriba, J. L. G., Marquez-Rodas, I., Soria, A., Algarra, S. M.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/156158
Acceso en línea:https://hdl.handle.net/11441/156158
https://doi.org/10.1007/s12094-017-1768-1
Access Level:acceso abierto
Palabra clave:Melanoma
Metastatic
Adjuvant
Immunotherapy
B-RAF
Descripción
Sumario:All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic mel anoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams

Similares en LA Referencia